Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $3.44M invested in Sonoma Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
62% more capital invested
Capital invested by funds: $2.12M → $3.44M (+$1.32M)
20% more funds holding
Funds holding: 15 → 18 (+3)
0.03% more ownership
Funds ownership: 0.05% → 0.08% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
+$1.01M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$120K |
| 3 |
Renaissance Technologies
New York
|
+$104K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$70.2K |
| 5 |
GW
GW & Wade
Wellesley,
Massachusetts
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$285K |
| 2 |
MCC
Malaga Cove Capital
Pv Estates,
California
|
-$45K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.71K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$856 |
SNOA Hedge Fund Activity: Q4 2017 in Review
18 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2017, worth a combined $3.44M — up 62% from $2.12M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SNOA positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Bard Associates, adding an estimated $1.01M. The largest seller was JW Asset Management, cutting an estimated $285K.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2017, up from 15 in Q3 2017.
- Funds reported $3.44M of Sonoma Pharmaceuticals stock for Q4 2017, up 62% quarter-over-quarter.
- 5 funds opened new Sonoma Pharmaceuticals positions in Q4 2017 and 2 closed out, a net change of +3 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2017 was Bard Associates, an estimated $1.01M added.
- The largest Sonoma Pharmaceuticals seller in Q4 2017 was JW Asset Management, an estimated $285K sold.
Based on aggregated 13F filings for Q4 2017.